Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 billion in 2022. M&A activity jumped to $140 billion from $78 billion during the same period. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about its Global Trends in R&D 2024 report, what he’s watching, and why the new patent cliff for the industry will be less threatening than the last one.
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Speaking of Psychology